#Haematology #multiplemyeloma #Sanofi #Sarclisa #isatuximab #drugdelivery #UK #subcutaneousSarclisa #SarclisaOBI #theonbodyinjector #OBI #CirCLIQOBIdevice #CirCLIQOBI #antiCD38antibody #OBIdevice #NHS10YearPlan #NationalCancerPlan #patientcentredinnovation
zurl.co/SnRig
zurl.co/SnRig
UK will be first market for Sanofi's subcutaneous Sarclisa
Sanofi's on-body injector version of multiple myeloma therapy Sarclisa has been cleared in the UK, which will be the first market for the product.
pharmaphorum.com
June 19, 2026 at 9:07 AM